



***BioAlliance Pharma presents results on a new quinoline family on
HIV integrase inhibitors
at the 16th Conference on Retroviruses and Opportunistic Infections (CROI)***

Paris, February 6, 2009 - BioAlliance Pharma SA (Euronext Paris-BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announces the presentation of its results on a new quinoline family acting as HIV integrase inhibitors at the 16th Conference on Retroviruses and Opportunistic Infections (CROI), in Montreal, Canada (February 8 to 11, 2009).

The emergence of resistance mutations against available antiretroviral drugs brings out the need to develop new therapeutic targets. HIV integrase inhibitors open up a new way as a promising class of antiretroviral drugs. They act by blocking the action of the integrase, a viral enzyme that inserts the viral genome into the DNA of the host cell preventing so the formation of the provirus. The development of safe and efficient integrase inhibitors will allow to propose new therapies targeting simultaneously the three key viral enzymes, and thus to strongly reduce emerging acquired resistance.

The presented data show the activity of quinolines, a new HIV integrase inhibitor family. Their peculiar mechanism of action permits them to keep their activity on viruses resisting to the other antiretroviral drug classes and on viruses resisting to the integrase inhibitor (Isentress[®], raltegravir - Merck and Co) presently on the market.

The poster: "A New Quinoline Family of HIV-1 Integrase Inhibitors Acting on HIV-1 Mutants Selected by Integrase Strand Transfer Inhibitors" will be on line on BioAlliance website on February 8, 2009.

About the 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)

The Conference on Retroviruses and Opportunistic Infections is a scientifically focused meeting of the world's leading researchers working to understand, prevent, and treat HIV/AIDS and its complications. The mission of the Retrovirus Conference is to provide a forum for basic scientists and clinicians to present, discuss, and critique their investigations into the biology and epidemiology of human retroviruses and the diseases they produce with the ultimate goal of transplanting laboratory and clinical research into progress against the AIDS epidemic.

About BioAlliance Pharma

A privileged partner for hospital specialists, BioAlliance Pharma is a specialty biopharmaceutical company, which develops and markets innovative products more especially in the fields of opportunistic infections or chemotherapy complications. Our targeted approaches, in areas where medical needs are insufficiently met, contribute to overcoming drug resistance and improving health and quality of life for patients. BioAlliance Pharma's ambition is to become a leading player in Europe in these fields by aligning innovation with patients' needs.

For more information, visit BioAlliance Pharma's website at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com